Oral LNAD+ Boosts Intracellular NAD by 53% in 6 Days Without Raising Plasma NAD
A phase 0/1b RCT finds a novel oral NAD+ formulation rapidly elevates intracellular NAD in whole blood while leaving plasma NAD unchanged.
Summary
NAD+ levels decline with age, contributing to metabolic dysfunction. Standard NAD precursors like NR and NMN must be converted before raising cellular NAD, creating biosynthetic bottlenecks. This randomized controlled trial tested LNAD+, a physicochemically modified form of NAD+ designed for better cellular uptake, in 50 healthy adults aged 45–75. After just 5 days of oral supplementation, intracellular NAD in whole blood rose 53% versus placebo — a large effect size. Notably, plasma NAD levels were unchanged, suggesting the compound is taken up directly into cells rather than circulating freely. Markers of NAD metabolism in plasma also increased, confirming biological activity. The supplement was well tolerated with minimal side effects. These findings suggest LNAD+ may offer a more direct route to cellular NAD restoration than current precursor approaches.
Detailed Summary
NAD+ is a critical coenzyme involved in energy metabolism, DNA repair, and cellular stress responses. Its decline with aging is well established and is linked to a range of age-related conditions. Boosting NAD+ has become a key target in longevity medicine, but existing strategies using precursors such as NR or NMN rely on enzymatic conversion steps that can limit efficacy.
This phase 0/1b double-blind, placebo-controlled trial (RENEWAL-NAD+) enrolled 60 healthy adults aged 45–75, with 50 included in the primary analysis. Participants received 5 days of oral LNAD+ — a proprietary formulation called LathMized® NAD+ that alters the supramolecular organization of NAD+ while preserving its molecular structure — or placebo. Primary endpoints were changes in intracellular NAD (measured in whole blood) and circulating NAD (measured in plasma).
The most striking result was a 53% increase in intracellular NAD versus placebo at Day 6, with a very large effect size (Hedges' g = 3.66, p < 0.001). In contrast, plasma NAD was statistically unchanged, demonstrating compartment-selective augmentation. Plasma NAD catabolites — including 1-methyl-nicotinamide and N1-methyl-2-pyridone-5-carboxamide — rose substantially, providing pharmacodynamic confirmation of downstream NAD metabolic flux. The two compartments showed distinct physiological correlates: circulating NAD tracked inflammatory and metabolic markers, while intracellular NAD correlated with red blood cell indices and nicotinamide.
Tolerance was excellent. Adverse event rates were comparable between groups, and only one mild adverse event (Grade 1 nausea) occurred in the LNAD+ arm. No secondary clinical, vital-sign, or wearable-derived endpoints survived multiplicity correction after 5 days.
While the results are compelling, important caveats apply. The trial was short (5 days), the sample was relatively small, and multiple authors hold financial relationships with the commercial entity behind LNAD+. Longer trials with hard clinical endpoints are needed to validate whether rapid intracellular NAD elevation translates to meaningful healthspan or clinical benefits.
Key Findings
- Oral LNAD+ raised intracellular NAD by 53% versus placebo at Day 6 (Hedges' g = 3.66).
- Plasma NAD levels were unchanged, indicating compartment-selective, direct cellular uptake.
- NAD metabolic flux markers in plasma rose significantly, confirming biological activity downstream.
- Intracellular and plasma NAD compartments had distinct physiological correlates in exploratory analyses.
- Only one mild adverse event occurred; safety profile was comparable to placebo over 5 days.
Methodology
Double-blind, randomized, placebo-controlled Phase 0/1b trial in 60 healthy adults aged 45–75 (primary analysis n=50); participants received 5 days of oral LNAD+ or placebo. Primary endpoints were intracellular NAD (whole blood) and circulating NAD (plasma), with extensive plasma metabolomics for exploratory analyses. The trial was retrospectively registered on ClinicalTrials.gov.
Study Limitations
The trial lasted only 5 days and included 50 participants, making it underpowered to detect clinical outcomes or long-term effects. Multiple authors have financial stakes in BioNADRx, the commercial entity developing LNAD+, creating a significant conflict of interest. This summary is based on the abstract only, as the full paper was not available; methodology and data details could not be fully evaluated.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: